Img 7289 WEB Nov 13 2019 nbsp 0183 32 IMG 7289 CTP 102 is an ongoing multi center open label study that recently transitioned from a Phase 1 2a dose range finding study to a Phase 2b study of IMG 7289 administered orally once daily in adult patients with intermediate 2 or high risk MF resistant to or intolerant of ruxolitinib
WEB Aims IMG 7289 CTP 102 is an ongoing global open label Phase 2 study evaluating bomedemstat dosed QD in MF patients NCT03136185 Key eligibility criteria include patients intolerant refractory resistant or inadequately controlled by approved therapy and platelet count 100 x 109 L Key objectives are safety and reduction of spleen WEB IMG 7289 bomedemstat is an orally active LSD1 inhibitor that in mouse models of MPNs reduced peripheral cell counts splenomegaly inflammatory cytokines marrow fibrosis and importantly mutant cell burdens Jutzi et al 2018
Img 7289
Img 7289
[img-1]
WEB Jul 24 2020 nbsp 0183 32 A phase 2 study of bomedemstat IMG 7289 a lysine specific demethylase 1 LSD1 inhibitor for the treatment of later stage myelofibrosis MF Presented at 2020 European Hematology
Pre-crafted templates offer a time-saving solution for creating a varied series of documents and files. These pre-designed formats and layouts can be used for different individual and professional jobs, consisting of resumes, invitations, flyers, newsletters, reports, discussions, and more, improving the material production process.
Img 7289
[img_title-6]
[img_title-7]
[img_title-8]
[img_title-9]
[img_title-11]
[img_title-12]
https://ashpublications.org › blood › article
WEB Nov 15 2022 nbsp 0183 32 Lysine specific demethylase 1 LSD1 is a histone demethylase critical for self renewal potential of malignant stem cells and progenitor maturation Bomedemstat is an oral LSD1 inhibitor clinically active in patients with MPNs IMG 7289 CTP 102 is a global open label Phase 2 study evaluating bomedemstat dosed in MF patients NCT03136185
https://ashpublications.org › blood › article
WEB Nov 5 2021 nbsp 0183 32 IMG 7289 CTP 201 is a global open label Phase 2b study of bomedemstat taken once daily for 24 weeks in patients with ET who are resistant to or intolerant of at least one SOC treatment NCT04254978
https://www.ncbi.nlm.nih.gov › pmc › articles
WEB Jun 23 2022 nbsp 0183 32 IMG 7289 CTP 201 is an ongoing global open label Phase 2b study of bomedemstat taken QD for 24 weeks in patients with ET who are resistant intolerant to at least one standard treatment NCT04254978
https://www.sciencedirect.com › science › article › pii
WEB Nov 23 2021 nbsp 0183 32 IMG 7289 CTP 102 is a global open label Phase 1 2 study evaluating bomedemstat dosed once daily in MF patients NCT03136185 Data from this ongoing study are presented
https://www.sciencedirect.com › science › article › pii
WEB Nov 2 2023 nbsp 0183 32 IMG 7289 CTP 201 was a global open label Phase 2b study of bomedemstat IMG 7289 MK 3543 taken once daily for 24 weeks in patients with ET resistant to or intolerant of at least one standard treatment NCT04254978
WEB Jan 15 2020 nbsp 0183 32 This is a Phase 2b open label study of an orally administered LSD1 inhibitor Bomedemstat MK 3543 formerly called IMG 7289 in patients with essential thrombocythemia This study investigates the following The safety and tolerability of Bomedemstat The pharmacodynamic effect of Bomedemstat WEB IMG 7289 bomedemstat is an orally active LSD1 inhibitor that reduced peripheral cell counts splenomegaly inflammatory cytokines and mutant cell burdens in mouse models of MPNs Jutzi et al 2018
WEB Feb 2 2023 nbsp 0183 32 Bomedemstat also known as IMG 7289 Figure 8 Hiatt et al 2022 is an oral small molecule irreversible LSD1 inhibitor IC 50 56 8 nM developed by Imago BioSciences in clinical trials for myeloid related malignancies Table 1